ArticleRSC advances2024
A dual-function chromogenic and fluorogenic benzofurazan probe for plazomicin and its innovative utility for development of two microwell assays with high throughput for analysis of drug substance and pharmaceutical formulations.
Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plazomicin (PLZ) is a novel aminoglycoside which has been recently approved by The US Food and Drug Administration for the treatment of complicated urinary tract infections including acute pyelonephritis, caused by certain Enterobacteriaceae, in adult patients with limited or no options for alternative treatment. This study focuses on the development of microwell-based photometric and fluorometric assays for the quantitative determination of PLZ in its bulk drug substance and commercial pharmaceutical formulations (Zemedri® injections). Both assays utilize the dual-function chromogenic and fluorogenic properties of the 4-fluoro-7-nitrobenzofurazan (NBD-F) probe. The reaction between PLZ and NBD-F, conducted in a borate buffer at pH 8, resulted in the formation of a colored and fluorescent reaction product. The product exhibited maximum light absorption at 473 nm and emitted fluorescence at 541 nm when excited at 473 nm. Factors influencing the reaction between PLZ and NBD-F were thoroughly investigated, and optimal conditions were determined. Under the optimized reaction conditions, calibration curves were generated to establish the relationship between absorbance and fluorescence intensities of the reaction product with the corresponding PLZ concentrations. The absorbance-concentration relation was linear in a PLZ concentration range of 20-800 μg mL
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.